Physician profile
Douglas Le
NPI 1730649765
$6,118.45
in general payments reported to CMS, 2019-2025
33 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9.36 · 2021: $256 · 2022: $781 · 2023: $1,773 · 2024: $1,633 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,072.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,025.15 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $647.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $577.57 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $574.80 | 2022-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $445.85 | 2022-2025 | |
| Glaxosmithkline, LLC. | $373.51 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $370.85 | 2023-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.18 | 2022-2025 | Jardiance |
| Pfizer INC. | $247.15 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $193.49 | 2021-2024 | Xarelto |
| Abbott Laboratories | $192.70 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $145.91 | 2023 | Quviviq |
| Insmed, INC. | $139.05 | 2023 | Arikayce |
| Edwards Lifesciences Corporation | $112.39 | 2021 | |
| Intuitive Surgical, INC. | $112.15 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $81.56 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $77.73 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $67.51 | 2024 | Inspire |
| Astellas Pharma US INC | $63.25 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $47.17 | 2023-2024 | |
| Renalytix Ai, INC. | $40.84 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Alk-Abello, INC | $31.87 | 2025 | Ragwitek, Grastek, Odactra |
| Seqirus USA INC | $31.35 | 2025 | Fluad, Flucelvax |
| Lucid Diagnostics INC. | $30.92 | 2023 | |
| Boston Scientific Corporation | $26.87 | 2025 | Opticross 35 |
| Puma Biotechnology, INC. | $22.12 | 2022 | |
| Phadia US INC. | $19.91 | 2025 | Immunocap |
| Csl Behring | $17.58 | 2021 | |
| Philips North America LLC | $17.21 | 2024 | (Ck7) Extended Holter |
| Kowa Pharmaceuticals America, INC. | $15.84 | 2025 | Zoryve |
| Alnylam Pharmaceuticals INC. | $14.05 | 2025 | Givlaari |
| Esperion Therapeutics, INC. | $14.04 | 2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.